Today's news release revolves around Manas AI, an AI-powered drug discovery company. Co-founded by LinkedIn founder Reid Hoffman, cancer researcher and author of the book Siddhartha Mukherjee, The Manas AI raises $24.6 million in investments.
Manas AI
In the evergrowing world of Artificial Intelligence, AI has taken over all fields of life. The same goes for the co-founding of Manas AI, an AI-powered drug discovery startup that uses artificial intelligence to discover new medicinal drugs. Manas AI is co-founded by LinkedIn founder Reid Hoffman, a cancer researcher and the author of the book “The Emperor of All Maladies,” Siddhartha Mukherjee.
Manas AI Funding Investors
Manas AI has raised $24.6 million in seed funding from investors, including Hoffman, General Catalyst, and Greylock.
Manas AI Focus Areas of Work
AI-powered drug discovery startup Manas AI is lined to initially focus on developing treatments for breast cancer, prostate cancer, and lymphoma.
Manas AI uses AI to design molecules and test newly generated designs in a wet laboratory. The company will also improvise Microsoft's cloud computing platform, Azure, and its expertise to innovate new medicines, as reported by Hoffman during the presentation of his latest book “Superagency.”
Manas AI in Comparison to Other AI-Powered Drug Discovery Startups
As a startup company, Manas AI's investments are relatively small compared to other AI-powered drug discovery startups, and it is on the road to successfully making new medicinal drugs. Xaira launched with $1 billion in initial funding, while Treeline Biosciences raised $422 million.
Reid Hoffman's Ties to Microsoft
Reid Hoffman has worked with Microsoft and has close ties to Microsoft, which acquired his company LinkedIn in a profitable deal in 2016.